Biotechnology News

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

WELLESLEY HILLS, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...

REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Hinge Bio, Inc., a privately-held clinical-stage biotechnology company focused on the discovery and development of best-in-class antibody...

Trial met its dual primary endpoints for (1) statistically significant reduction (p=0.0168) in microglial activation as measured by TSPO PET imaging in patients treated with 50 ug nasal foralumab as...

Allowed claims cover Lowe syndrome and Dent disease 2; Can-Fite holds development, commercialization, and out-licensing rights for these indications under its agreement with Fondazione Telethon Ramat...

– Afimetoran, an investigational oral, once-daily, equipotent TLR7/8 inhibitor, targets a central driver of lupus biology with the potential to address both cutaneous and systemic disease – – Global,...

REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients...

Alvotech (NASDAQ: ALVO, ALVO SDB) kemur fram á fjórum alþjóðlegum fjárfestaráðstefnum í nóvember, í Bretlandi, Noregi og Svíþjóð. Alþjóðleg líftækniráðstefna UBS í London – samtal við greinanda...

REYKJAVIK, Iceland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for...

COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on September 1, 2026, has now been completed,...